Understanding the Role of Cancer and Myositis

Johns Hopkins rheumatologist Lisa Christopher-Stine shares what is known about how the disease processes of cancer and myositis intertwine. It has been known that certain types of myositis, such as dermatomyositis, increase the risk of cancer, and certain auto antibodies such as nuclear matrix protein 2 (NXP2) or transcription intermediary factor 1 (TIF1) gamma confer a higher risk for cancer. More recently, experts at Johns Hopkins have identified two additional antibodies that seem to modify the risk for developing cancer, even among those who seem to be at the highest risk of developing it. Christopher-Stine breaks down what this means for patients and their treating physicians.

Related Presenters

Lisa Christopher, M.D., M.P.H..

Lisa Christopher, M.D., M.P.H.

Director, Johns Hopkins Myositis Precision Center of Excellence, Professor of Medicine

View full profile